OR WAIT null SECS
March 16, 2023
27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.
March 14, 2023
FDA has approved Acadia Pharmaceuticlas’ Daybue (trofinetide), the first treatment for Rett syndrome, a rare genetic disorder.
FDA has approved Pfizer’s ZAVZPRET (zavegepant), a new nasal spray treatment for migraine.
FDA is seeking $7.2 billion to enhance food safety and advance medical product availability.
Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.
March 13, 2023
Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
March 10, 2023
Even after an FDA advisory panel voted 14–1 in October 2022 to remove the drug, Makena manufacturer Covis Pharma continued to press for some continued access to the therapy.
March 09, 2023
Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies.
Vetter has become a participant of the UN Global Compact Network.
Congressional leaders are investigating how pharmacy benefit managers determine health plan coverage and charges for medicines.